Floatz logo

Tolododekin Alfa

Cutaneous Tumor

Ankyra Therapeutics, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Cutaneous Tumor cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
TACROLIMUS
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Rapamycin
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4BB
Difluoromethylornithine
University of Wisconsin, Madison
Phase 2B
TRASTUZUMAB
Cancer Research UK
Phase 2/3B

View all 24 →

Same molecule, other indications

Tolododekin Alfa is also rated in:

metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
soft tissue neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →